Glofitamab before stem cell transplant for relapsed DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- You have tried at least two different cancer treatments, but the lymphoma has come back or hasn't fully responded.
- You are between 18 and 70 years old.
- You have not had a stem cell transplant before.
- You are generally well enough to do most daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
This trial studies whether adding the drug glofitamab before and after a stem cell transplant can help people with certain types of relapsed or hard-to-treat B-cell lymphoma. The goal is to see if it improves the chance of keeping the lymphoma from coming back.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
Hear when a new Diffuse Large B-cell Lymphoma(DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.